These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 36032486)

  • 1. Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease.
    Raji YR; Ajayi SO; Adeoye AM; Amodu O; Tayo BO; Salako BL
    Afr Health Sci; 2022 Mar; 22(1):344-351. PubMed ID: 36032486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
    Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of CKD-MBD in pre-dialysis patients using biochemical markers in Enugu, South-East Nigeria.
    Okoye JU; Arodiwe EB; Ulasi II; Ijoma CK; Onodugo OD
    Afr Health Sci; 2015 Sep; 15(3):941-8. PubMed ID: 26957985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examining the effects of uric acid-lowering on markers vascular of calcification and CKD-MBD; A post-hoc analysis of a randomized clinical trial.
    Andrews ES; Perrenoud L; Nowak KL; You Z; Pasch A; Chonchol M; Kendrick J; Jalal D
    PLoS One; 2018; 13(10):e0205831. PubMed ID: 30356327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial differences in markers of mineral metabolism in advanced chronic kidney disease.
    Jovanovich A; Chonchol M; Cheung AK; Kaufman JS; Greene T; Roberts WL; Smits G; Kendrick J;
    Clin J Am Soc Nephrol; 2012 Apr; 7(4):640-7. PubMed ID: 22383748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of Ronghuang Granule on serum FGF23, FGFRs and Klotho in non-dialysis patients with CKD-MBD and kidney deficiency and damp-heat syndrome].
    Hu S; Wang D; Zhang R; Cao Y; Jin H; Mao Y; Wei L; Ren K; Zhang X; Wang Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Dec; 38(12):1427-1432. PubMed ID: 30613009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profile of chronic kidney disease related-mineral bone disorders in newly diagnosed advanced predialysis diabetic kidney disease patients: A hospital based cross-sectional study.
    Ray S; Beatrice AM; Ghosh A; Pramanik S; Bhattacharjee R; Ghosh S; Raychaudhury A; Mukhopadhyay S; Chowdhury S
    Diabetes Metab Syndr; 2017 Dec; 11 Suppl 2():S931-S937. PubMed ID: 28728874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease.
    Manghat P; Fraser WD; Wierzbicki AS; Fogelman I; Goldsmith DJ; Hampson G
    Osteoporos Int; 2010 Nov; 21(11):1853-61. PubMed ID: 20012018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder?
    Figurek A; Spasovski G
    Int Urol Nephrol; 2018 Oct; 50(10):1863-1870. PubMed ID: 30030677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crosstalk between kidney and bone: insights from CKD-MBD.
    Suzuki K; Soeda K; Komaba H
    J Bone Miner Metab; 2024 Jul; 42(4):463-469. PubMed ID: 39060498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease.
    Graciolli FG; Neves KR; Barreto F; Barreto DV; Dos Reis LM; Canziani ME; Sabbagh Y; Carvalho AB; Jorgetti V; Elias RM; Schiavi S; Moysés RMA
    Kidney Int; 2017 Jun; 91(6):1436-1446. PubMed ID: 28318623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High C-Terminal Fibroblast Growth Factor-23, Intact Parathyroid Hormone, and Interleukin-6 as Determinants of Valvular Calcification in Regular Hemodialysis Patients.
    Kandarini Y; Mahadita GW; Herawati S; Wibhuti IBR; Widiana IGR; Ayu NP
    Int J Gen Med; 2022; 15():4227-4236. PubMed ID: 35480992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.
    Isakova T; Cai X; Lee J; Mehta R; Zhang X; Yang W; Nessel L; Anderson AH; Lo J; Porter A; Nunes JW; Negrea L; Hamm L; Horwitz E; Chen J; Scialla JJ; de Boer IH; Leonard MB; Feldman HI; Wolf M;
    Am J Kidney Dis; 2020 Feb; 75(2):235-244. PubMed ID: 31668375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of plasma neutrophil gelatinase-associated lipocalin with parameters of CKD-MBD in maintenance hemodialysis patients.
    Jia XY; Wei K; Chen J; Xi LH; Kong XL; Wei Y; Wang L; Wang ZS; Liu YP; Liang LM; Xu DM
    J Bone Miner Metab; 2021 Nov; 39(6):1058-1065. PubMed ID: 34392464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGF-23 and Phosphate in Children with Chronic Kidney Disease: A Cross-Sectional Study in Kazakhstan.
    Balmukhanova A; Kabulbayev K; Alpay H; Kanatbayeva A; Balmukhanova A
    Medicina (Kaunas); 2020 Dec; 57(1):. PubMed ID: 33379157
    [No Abstract]   [Full Text] [Related]  

  • 16. Activin A: a marker of mineral bone disorder in children with chronic kidney disease?
    Shankar R; Saha A; Dhull RS; Shroff R; Nangia A; Sharma S
    Pediatr Nephrol; 2024 Sep; 39(9):2773-2777. PubMed ID: 38744714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients.
    Kanda E; Yoshida M; Sasaki S
    BMC Nephrol; 2012 Sep; 13():122. PubMed ID: 23013306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diabetic Kidney Disease 3rd stage - laboratory markers of mineral bone disorder].
    Klimentová A; Ságová I; Prídavková D; Kantárová D; Makovický P; Sadloňová J; Mokáň M
    Vnitr Lek; 2016; 62(6):442-8. PubMed ID: 27485841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-1 inhibition, chronic kidney disease-mineral and bone disorder, and physical function
.
    Nowak KL; Hung A; Ikizler TA; Farmer-Bailey H; Salas-Cruz N; Sarkar S; Hoofnagle A; You Z; Chonchol M
    Clin Nephrol; 2017 Sep; 88(9):132-143. PubMed ID: 28699886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease.
    Hong YA; Lim JH; Kim MY; Kim Y; Yang KS; Chung BH; Chung S; Choi BS; Yang CW; Kim YS; Chang YS; Park CW
    Clin Exp Nephrol; 2015 Apr; 19(2):208-15. PubMed ID: 24682550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.